A prophylactic hepatitis B vaccine with a novel adjuvant system

Vaccine

Volumn 19, Issue 17-19, 2001, Pages 2400-2403

  Thoelen, Stefaan ^a   De Clercq, Norbert ^a   Tornieporth, Nadia ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adjuvant system; Engerix B; Hepatitis B vaccine

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; PHOSPHORYL LIPID A; RECOMBINANT HEPATITIS B VACCINE; SMITHKLINE BEECHAM ADJUVANT SYSTEM 4; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; HEMODIALYSIS PATIENT; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFECTION RISK; NORMAL HUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALUM COMPOUNDS; CLINICAL TRIALS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNITY, CELLULAR; LIPID A; MIDDLE AGED; SAFETY; VACCINES, SYNTHETIC;

EID: 0035925605     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00462-X     Document Type: Conference Paper

References (17)

1. Global programme for control of hepatitis B infection
2. Over a decade of experience with a yeast recombinant hepatitis B vaccine
3. Long term follow-up (11-13 years) of high-risk neonates vaccinated against hepatitis B
4. Meta-analysis of published clinical studies on two yeast-derived hepatitis B vaccines to determine attainable seroprotection rates
5. Adjuvants for human vaccines - Current status, problems and future prospects
6. Biological activities of monophosphoryl Lipid A
7. A critical determinant of lipid A endotoxic activity. Cellular and molecular aspects of endotoxin reactions
8. The adjuvant properties of a non-toxic monophosphoryl lipid A in hyporesponsive and aging mice
9. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system
10. A hepatitis B vaccine formulated with a novel adjuvant system
11. A hepatitis B vaccine with a novel adjuvant: immunogenicity and reactogenicity profile in adult vaccine non-responders
12. Response to hepatitis B vaccine: Multiple HLA genes are involved
13. Contribution of human leucocyte antigens to the antigen response to hepatitis B vaccination
14. HLA DQ2 positive subjects vaccinated with a hepatitis B vaccine with a novel adjuvant (HBsAg/SBAS4)
15. Immunogenicity and reactogenicity of the novel adjuvanted hepatitis B vaccine (HBsAg/SBAS4), compared to that of Engerix-B in older adults aged 50-70 years
16. Are booster immunisations needed for lifelong hepatitis B immunity